Esophagus leiomyosarcoma

disease
On this page

Also known as esophageal leiomyosarcomaleiomyosarcoma of esophagusleiomyosarcoma of oesophagusleiomyosarcoma of the esophagusleiomyosarcoma of the oesophagus

Summary

Esophagus leiomyosarcoma (MONDO:0003365) is a disease. A subtype of esophagus sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameesophagus leiomyosarcoma
Mondo IDMONDO:0003365
DOIDDOID:5276
ICD-111419925892
NCITC5334
UMLSC1333454
MedGen272589
GARD0023479
Anatomy (UBERON)UBERON:0001043
Is cancer (heuristic)no

Also known as: esophageal leiomyosarcoma · esophagus leiomyosarcoma · leiomyosarcoma of esophagus · leiomyosarcoma of oesophagus · leiomyosarcoma of the esophagus · leiomyosarcoma of the oesophagus

Disease family

This is a subtype of esophagus sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderdigestive system canceresophageal canceresophagus sarcomaesophagus leiomyosarcoma

Related subtypes (1): esophagus liposarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.